GI Dynamics Appoints Juliet Thompson to Company’s Board of Directors
August 22 2017 - 6:10PM
Business Wire
GI Dynamics® Inc. (ASX:GID), a medical device company that
commercialized EndoBarrier® in Europe, the Middle East and South
America for patients with type 2 diabetes and obesity announces the
appointment of medical and financial markets veteran Juliet
Thompson to the company’s board of directors, effective
immediately.
Thompson has assumed the role of non-executive director (NED)
and the role of chair of the GI Dynamics audit committee. Graham
Bradley, former chair of the audit committee, will remain as a
member of the committee to ensure continuity.
Thompson, a chartered accountant, is also NED of Nexstim
Limited, a medical technology company quoted on Nasdaq First North
Finland and Nasdaq First North Sweden, NED of Novacyt SA, a
diagnostic company, listed on Euronext, and is the chair of Premier
Veterinary Group plc, the London Stock Exchange listed provider of
services to third-party veterinary practices. Thompson has advised
and raised capital for healthcare companies for more than 20 years
and founded Code Securities, a healthcare investment banking firm
that was sold to Nomura.
After the sale to Nomura, she served as head of corporate
finance and managing director on the board of Nomura Code, which
executed more than 150 life science financing transactions,
including 40 IPOs, raising more than €4 billion. In her final role,
she led the European health care practice at Stifel, a diversified
financial services holding company.
Thompson resides in the UK and brings significant experience
with London capital markets to the GI Dynamics board of
directors.
“Ms. Thompson brings significant experience in healthcare,
entrepreneurial development and capital markets, most notably on
the London-based AIM market,” said Dan Moore, chair of GI Dynamics.
“She has also led the development of numerous ventures and has a
wealth of early-stage experience that is relevant to the
development of GI Dynamics.”
“We look forward to working with Ms. Thompson over the coming
years as we position GI Dynamics and EndoBarrier to best serve the
rapidly growing patient population in the type 2 diabetes and
obesity space,” said Moore.
“Over the past few months, I have reviewed the type 2 diabetes
and obesity market, EndoBarrier, the leadership team and evaluated
the history of GI Dynamics. I reached the conclusion that this is a
great opportunity with a highly experienced and engaged team with
significant potential for patient benefit and investor upside. I’m
excited to join and help guide the company,” said Thompson. “I look
forward to working with the GI Dynamics board and leadership team
as we work to appropriately capitalize GI Dynamics and lead the
company into the future.”
About GI Dynamics
GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the
first endoscopically-delivered device approved for the treatment of
type 2 diabetes and obesity. EndoBarrier is not approved for sale
in the United States and is limited by federal law to
investigational use only in the United States. Founded in 2003, GI
Dynamics is headquartered in Boston, Massachusetts. For more
information, please visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements. These
forward-looking statements are based on GI Dynamics management’s
current estimates and expectations of future events as of the date
of this announcement. Furthermore, the estimates are subject to
several risks and uncertainties that could cause actual results to
differ materially and adversely from those indicated in or implied
by such forward-looking statements. These risks and uncertainties
include but are not limited to, risks associated with obtaining
funding from third parties; the consequences of stopping the ENDO
trial and the possibility that future clinical trials will not be
successful or confirm earlier results; the timing and costs of
clinical trials; the timing of regulatory submissions; the timing,
receipt and maintenance of regulatory approvals; the timing and
amount of other expenses; the timing and extent of third-party
reimbursement; risks associated with commercial product sales,
including product performance, competition, market acceptance of
products, intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size of
the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170822006222/en/
GI Dynamics Inc.Investor RelationsUnited States:Janell
Shields, +1 781-357-3280investor@gidynamics.com
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024